Biomarkers for Salvage Therapy in Testicular Germ Cell Tumors.
biomarkers
germ cell tumors
immunotherapy
microRNA
molecular alterations
salvage therapy
testicular cancers
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
28 Nov 2023
28 Nov 2023
Historique:
received:
22
10
2023
revised:
24
11
2023
accepted:
25
11
2023
medline:
9
12
2023
pubmed:
9
12
2023
entrez:
9
12
2023
Statut:
epublish
Résumé
The outcome of metastatic testicular germ cell tumor patients has been dramatically improved by cisplatin-based chemotherapy combinations. However, up to 30% of patients with advanced disease relapse after first-line therapy and require salvage regimens, which include treatments with conventional-dose chemotherapy or high-dose chemotherapy with autologous stem cell transplantation. For these patients, prognosis estimation represents an essential step in the choice of medical treatment but still remains a complex challenge. The available histological, clinical, and biochemical parameters attempt to define the prognosis, but they do not reflect the tumor's molecular and pathological features and do not predict who will exhibit resistance to the several treatments. Molecular selection of patients and validated biomarkers are highly needed in order to improve current risk stratification and identify novel therapeutic approaches for patients with recurrent disease. Biomolecular biomarkers, including microRNAs, gene expression profiles, and immune-related biomarkers are currently under investigation in testicular germ cell tumors and could potentially hold a prominent place in the future treatment selection and prognostication of these tumors. The aim of this review is to summarize current scientific data regarding prognostic and predictive biomarkers for salvage therapy in testicular germ cell tumors.
Identifiants
pubmed: 38069192
pii: ijms242316872
doi: 10.3390/ijms242316872
pmc: PMC10706346
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Cancer Commun (Lond). 2021 Mar;41(3):199-217
pubmed: 33506604
J Clin Oncol. 2009 May 1;27(13):2129-36
pubmed: 19289622
J Clin Oncol. 2010 Nov 20;28(33):4906-11
pubmed: 20956623
Nat Rev Cancer. 2019 Sep;19(9):522-537
pubmed: 31413324
Clin Genitourin Cancer. 2017 Jun;15(3):411-416.e2
pubmed: 28237180
J Clin Oncol. 2021 May 10;39(14):1563-1574
pubmed: 33822655
Cell Rep. 2018 Jun 12;23(11):3392-3406
pubmed: 29898407
Nat Rev Cancer. 2005 Mar;5(3):210-22
pubmed: 15738984
Urology. 2020 Oct;144:111-116
pubmed: 32721511
Cell Oncol (Dordr). 2017 Aug;40(4):341-355
pubmed: 28536927
Cell Oncol (Dordr). 2017 Aug;40(4):379-388
pubmed: 28612337
Ann Oncol. 2005 Jan;16(1):146-51
pubmed: 15598952
Cancers (Basel). 2022 Feb 21;14(4):
pubmed: 35205839
J Cancer Res Clin Oncol. 2016 Aug;142(8):1673-95
pubmed: 26660324
Cancer Med. 2019 Jul;8(7):3511-3519
pubmed: 31070303
J Clin Oncol. 2005 Sep 20;23(27):6549-55
pubmed: 16170162
J Clin Oncol. 2019 Jun 1;37(16):1412-1423
pubmed: 30875280
Ann Oncol. 2022 Apr;33(4):362-375
pubmed: 35065204
In Vivo. 2006 Nov-Dec;20(6A):697-701
pubmed: 17203748
Front Immunol. 2020 Sep 02;11:1568
pubmed: 32983080
Nat Commun. 2020 May 4;11(1):2189
pubmed: 32366847
Oncoimmunology. 2018 Dec 13;8(2):e1542245
pubmed: 30713803
Int J Cancer. 2020 Jul 15;147(2):423-439
pubmed: 31721169
Oncoimmunology. 2018 Feb 16;7(5):e1423169
pubmed: 29721375
Ann Oncol. 2016 Feb;27(2):300-5
pubmed: 26598537
Oncoimmunology. 2018 Jun 20;7(12):e1396403
pubmed: 30524878
J Clin Oncol. 2016 Nov 20;34(33):4000-4007
pubmed: 27646943
Oncol Lett. 2019 Aug;18(2):1497-1502
pubmed: 31423216
ACS Nano. 2017 Sep 26;11(9):8560-8578
pubmed: 28829568
Br J Cancer. 2018 Mar 20;118(6):831-838
pubmed: 29485980
Oncoimmunology. 2017 Mar 20;6(4):e1305535
pubmed: 28507813
Cancer. 2017 Jun 15;123(12):2190-2192
pubmed: 28513824
Front Immunol. 2023 Feb 13;14:1118610
pubmed: 36860862
Int J Mol Sci. 2022 Mar 03;23(5):
pubmed: 35269947
Transplantation. 2009 Jun 27;87(12):1778-86
pubmed: 19543053
Ann Oncol. 2008 Feb;19(2):259-64
pubmed: 18042838
Andrology. 2023 May;11(4):651-667
pubmed: 35930290
Int J Exp Pathol. 2000 Jun;81(3):211-7
pubmed: 10971742
Cancers (Basel). 2021 Oct 18;13(20):
pubmed: 34680371
Mol Oncol. 2022 Feb;16(3):683-698
pubmed: 34482638
Oncotarget. 2016 Jul 27;8(35):58037-58049
pubmed: 28938535
Cancer Med. 2018 Dec;7(12):6247-6257
pubmed: 30430771
Clin Epigenetics. 2021 Apr 6;13(1):70
pubmed: 33823933
Cancers (Basel). 2021 Apr 07;13(8):
pubmed: 33916925
Int J Mol Sci. 2021 Oct 29;22(21):
pubmed: 34769213
Am J Clin Pathol. 2011 Jan;135(1):119-25
pubmed: 21173133
Curr Oncol. 2020 Dec 21;28(1):107-114
pubmed: 33622996
Br J Cancer. 2023 Jun;128(12):2270-2282
pubmed: 37024667
J Clin Oncol. 2011 Jun 1;29(16):2178-84
pubmed: 21444870
HPB (Oxford). 2011 Sep;13(9):643-50
pubmed: 21843265
Front Oncol. 2018 Nov 28;8:571
pubmed: 30547014
World J Urol. 2022 Feb;40(2):373-383
pubmed: 35084545
Cell Death Dis. 2018 Sep 20;9(10):962
pubmed: 30237497
Eur Urol. 2006 Nov;50(5):1032-8; discussion 1038-9
pubmed: 16757095
Cell Signal. 2014 May;26(5):903-11
pubmed: 24462707
Front Oncol. 2020 Aug 14;10:1325
pubmed: 32923384
Int J Mol Sci. 2023 Jan 27;24(3):
pubmed: 36768818
Am J Clin Pathol. 2020 Feb 8;153(3):387-395
pubmed: 31802108
Genes Cancer. 2018 May;9(5-6):176-189
pubmed: 30603054
Int J Mol Sci. 2022 Nov 01;23(21):
pubmed: 36362130
Oncologist. 2019 Apr;24(4):e142-e145
pubmed: 30659078
Onco Targets Ther. 2018 Oct 16;11:7005-7009
pubmed: 30410357
Br J Cancer. 2018 Mar 20;118(6):825-830
pubmed: 29485982
Oncotarget. 2017 Mar 28;8(13):21794-21805
pubmed: 28423520
Eur Urol. 2012 May;61(5):1068-9
pubmed: 22386195
Epigenetics. 2021 Oct;16(10):1071-1084
pubmed: 33126827
J Clin Oncol. 2019 Jun 1;37(16):1432-1435
pubmed: 31009274
Cancer Lett. 2019 Jul 10;454:37-43
pubmed: 30978440
Mol Cancer. 2011 May 15;10:52
pubmed: 21575166
Br J Cancer. 2015 Jul 28;113(3):411-3
pubmed: 26171934
Cancers (Basel). 2019 Oct 11;11(10):
pubmed: 31614500
Cancers (Basel). 2019 Jun 08;11(6):
pubmed: 31181810
Br J Cancer. 2005 Aug 22;93(4):412-7
pubmed: 16106248
Cancer Treat Res Commun. 2018;17:8-12
pubmed: 30173005
Mol Oncol. 2022 Sep;16(17):3107-3127
pubmed: 35811571
J Urol. 2015 Jan;193(1):331-7
pubmed: 25046619
J Cell Physiol. 2013 Dec;228(12):2294-304
pubmed: 23625774
Ann Oncol. 2014 May;25(5):987-91
pubmed: 24595454
J Clin Oncol. 2022 Sep 10;40(26):3077-3087
pubmed: 35442716
J Clin Oncol. 2021 May 10;39(14):1553-1562
pubmed: 33729863
Cancer Immunol Res. 2016 Nov;4(11):903-909
pubmed: 27638840
Immunol Rev. 2017 Mar;276(1):97-111
pubmed: 28258697
Int Rev Immunol. 2015 Mar;34(2):154-87
pubmed: 25901860
J Clin Oncol. 2016 Feb 1;34(4):345-51
pubmed: 26460295
Front Oncol. 2022 Jun 10;12:910087
pubmed: 35756636
Crit Rev Oncol Hematol. 2005 Feb;53(2):141-64
pubmed: 15661565
J Clin Oncol. 1997 Feb;15(2):594-603
pubmed: 9053482
Anticancer Res. 2014 Jun;34(6):2709-13
pubmed: 24922631